Intech Investment Management LLC Sells 44,956 Shares of Palomar Holdings, Inc. $PLMR

Intech Investment Management LLC trimmed its holdings in shares of Palomar Holdings, Inc. (NASDAQ:PLMR) by 54.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,005 shares of the company’s stock after selling 44,956 shares during the quarter. Intech Investment Management LLC owned about 0.14% of Palomar worth $4,320,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Allworth Financial LP increased its holdings in shares of Palomar by 1,970.0% during the 2nd quarter. Allworth Financial LP now owns 207 shares of the company’s stock valued at $32,000 after acquiring an additional 197 shares during the last quarter. Salomon & Ludwin LLC bought a new stake in Palomar during the third quarter worth approximately $25,000. Richardson Financial Services Inc. raised its position in shares of Palomar by 210.0% in the third quarter. Richardson Financial Services Inc. now owns 217 shares of the company’s stock valued at $25,000 after purchasing an additional 147 shares during the period. Hollencrest Capital Management lifted its stake in shares of Palomar by 56.5% in the second quarter. Hollencrest Capital Management now owns 313 shares of the company’s stock worth $48,000 after buying an additional 113 shares during the last quarter. Finally, Clearstead Advisors LLC lifted its stake in shares of Palomar by 31.0% in the third quarter. Clearstead Advisors LLC now owns 397 shares of the company’s stock worth $46,000 after buying an additional 94 shares during the last quarter. Institutional investors and hedge funds own 90.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PLMR. JPMorgan Chase & Co. lifted their target price on shares of Palomar from $155.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, February 23rd. Weiss Ratings raised Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, January 14th. Evercore assumed coverage on Palomar in a report on Monday, February 9th. They issued an “outperform” rating and a $150.00 target price on the stock. Wall Street Zen downgraded Palomar from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Keefe, Bruyette & Woods upped their price target on Palomar from $170.00 to $171.00 and gave the stock an “outperform” rating in a report on Tuesday, January 6th. Seven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $163.00.

Insider Buying and Selling at Palomar

In other Palomar news, CFO T Christopher Uchida sold 783 shares of Palomar stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $128.04, for a total transaction of $100,255.32. Following the transaction, the chief financial officer directly owned 14,752 shares in the company, valued at approximately $1,888,846.08. The trade was a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Mac Armstrong sold 5,000 shares of Palomar stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $122.60, for a total value of $613,000.00. Following the transaction, the chief executive officer owned 343,388 shares in the company, valued at $42,099,368.80. This trade represents a 1.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 58,999 shares of company stock worth $7,253,229 in the last three months. 3.70% of the stock is owned by insiders.

Trending Headlines about Palomar

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Zacks Research raised FY2026 EPS to $9.00 (from $8.00) and boosted FY2027 to $9.60 and FY2028 to $12.60 — a sizeable multi‑year upgrade that implies stronger forward profitability. MarketBeat PLMR
• Positive Sentiment: Zacks lifted several near‑term quarterly estimates: Q1 2026 to $2.07 (from $1.89), Q2 2026 to $1.95 (from $1.87), and Q3 2026 to $2.67 (from $1.91). They also raised Q1–Q3 2027 quarterlies (Q1 2027 to $2.46, Q2 2027 to $2.30, Q3 2027 to $2.82), reflecting a consistent upward revision pattern. MarketBeat PLMR
• Neutral Sentiment: A Zacks feature summarizing Street views notes the average analyst price target implies roughly 36.2% upside for PLMR — a bullish signal for sentiment but not a guarantee of price moves. Wall Street Analysts Think Palomar Could Surge
• Negative Sentiment: Zacks trimmed its Q4 2026 estimate slightly to $2.30 from $2.34 — a modest downgrade that appears isolated versus broad upward revisions elsewhere. MarketBeat PLMR

Palomar Stock Performance

PLMR opened at $123.71 on Monday. The company has a fifty day moving average price of $128.55 and a two-hundred day moving average price of $123.21. The firm has a market capitalization of $3.30 billion, a PE ratio of 17.23 and a beta of 0.46. Palomar Holdings, Inc. has a 52 week low of $107.75 and a 52 week high of $175.85.

Palomar (NASDAQ:PLMR) last released its earnings results on Wednesday, February 11th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.18. The firm had revenue of $253.36 million for the quarter, compared to analyst estimates of $204.58 million. Palomar had a return on equity of 22.77% and a net margin of 22.50%.The company’s quarterly revenue was up 62.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.52 earnings per share. Equities analysts forecast that Palomar Holdings, Inc. will post 5.99 EPS for the current year.

Palomar Profile

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.